![](https://www.microbiometimes.com/wp-content/uploads/2018/04/scientist-2141259_960_720-326x245.jpg)
Pharma & Human Health
Symbiotix Biotherapies Announces License Agreement with Harvard University
Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix […]